Healthcare
ABIVAX Société Anonyme
ABVX$118.95+3.62%
Price is delayed.
Add to watchlist
About ABIVAX Société Anonyme
ABIVAX is a French biotechnology company that develops medicines for chronic inflammatory diseases like ulcerative colitis and Crohn's disease. Their main drug candidate, obefazimod, is being tested in clinical trials to see if it can help patients by adjusting how their immune systems work. The company was founded in 2013 and is based in Paris.
Loading chart...
Members only
Full research is for ConvictionStocks members
Members read the rest of this page. Where we have it for this company, that is:
- What each number means, in plain English, with the Wall Street name where the two differ.
- A plain-English summary of the company.
- How many analysts cover it, and the count behind each rating.
- Recent news, dated.
Get the free weekly market digest
The week's biggest movers, every Sunday. No spam.
Look up another company
Related Research
More Healthcare stocks to explore